{"log_id": 9033925578899770196, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 0.011942, "average": 0.95073, "min": 0.519103}, "location": {"width": 812, "top": 174, "height": 29, "left": 194}, "words": "刺感、红斑和或不影正常活动的不适。2级手足综食征定义为手和或足的疼痛性红斑科"}, {"probability": {"variance": 0.006904, "average": 0.961241, "min": 0.615005}, "location": {"width": 814, "top": 212, "height": 31, "left": 193}, "words": "肿胀和或影响患者日常生活的不适。3级手足综合征定义为手和或足湿性脱屑、溃疡、水"}, {"probability": {"variance": 0.013078, "average": 0.957136, "min": 0.475134}, "location": {"width": 582, "top": 253, "height": 27, "left": 193}, "words": "疱或严重的疼痛和或使患者不能工作或进行目常活动的严重不适"}, {"probability": {"variance": 0.000185, "average": 0.991731, "min": 0.940513}, "location": {"width": 777, "top": 291, "height": 32, "left": 234}, "words": "出现2级或3级手足综合征时应暂停使用卡培他滨,直至恢复正常或严重程度降至1"}, {"probability": {"variance": 0.01032, "average": 0.957101, "min": 0.505847}, "location": {"width": 813, "top": 331, "height": 30, "left": 193}, "words": "级。出现3级手足综合征后,再次使用卡培他滨时应降低剂量(见【用法用量1)。卡培他滨"}, {"probability": {"variance": 0.004725, "average": 0.971274, "min": 0.643693}, "location": {"width": 791, "top": 372, "height": 27, "left": 194}, "words": "与顺铂联合治疗时,针对手足综合征不建议使用维生素B6(吡哆醇)改善症状或二级预防"}, {"probability": {"variance": 0.000707, "average": 0.992264, "min": 0.876815}, "location": {"width": 406, "top": 414, "height": 24, "left": 194}, "words": "原因是有报道维生素B6可能降低顺铂的疗效"}, {"probability": {"variance": 0.014829, "average": 0.948984, "min": 0.422504}, "location": {"width": 772, "top": 451, "height": 26, "left": 235}, "words": "卡培他滨可引起高胆红素血症。如果药物相关的胆红素升高30ULN或转氨酶"}, {"probability": {"variance": 0.014544, "average": 0.938046, "min": 0.53693}, "location": {"width": 799, "top": 488, "height": 28, "left": 206}, "words": "ALT、AST)升高>2.5×ULN,应立即暂停使用卡培他滨。当胆红素降低至<3.0×LN或肝"}, {"probability": {"variance": 0.013596, "average": 0.938697, "min": 0.589552}, "location": {"width": 359, "top": 529, "height": 25, "left": 194}, "words": "转氨酶<2.5×ULN,可恢复使用卡培他滨"}, {"probability": {"variance": 0.014092, "average": 0.958122, "min": 0.465401}, "location": {"width": 766, "top": 567, "height": 26, "left": 241}, "words": "一项药物相互作用研究显示,卡培他滨与单剂量华法林联合给药时,S-华法林的平均"}, {"probability": {"variance": 0.007361, "average": 0.952864, "min": 0.654275}, "location": {"width": 815, "top": 605, "height": 27, "left": 194}, "words": "AUC显著增加(十57%)。研究结果提示该相互作用可能是由于卡培他滨对细胞色素P450-2C9"}, {"probability": {"variance": 0.006746, "average": 0.976484, "min": 0.502236}, "location": {"width": 814, "top": 645, "height": 27, "left": 194}, "words": "同工醇系统的抑制作用。对使用卡培他滨同时口服香豆素类衍生物抗凝剂的患者,应密切监"}, {"probability": {"variance": 0.003833, "average": 0.977696, "min": 0.634223}, "location": {"width": 664, "top": 683, "height": 27, "left": 194}, "words": "测其抗凝反应(INVR或PT),并相应调整抗凝剂的剂量(见【药物相互作用】)"}, {"probability": {"variance": 0.000402, "average": 0.993355, "min": 0.880815}, "location": {"width": 773, "top": 723, "height": 27, "left": 236}, "words": "应严密监测卡培他滨治疗的毒性反应。大多数不良反应是可逆的,虽然剂量可能需要限"}, {"probability": {"variance": 0.001247, "average": 0.985859, "min": 0.832901}, "location": {"width": 411, "top": 764, "height": 26, "left": 195}, "words": "制或降低,但无需终止用药(见【用法用量】)"}, {"probability": {"variance": 0, "average": 0.999478, "min": 0.998736}, "location": {"width": 113, "top": 803, "height": 25, "left": 195}, "words": "肾功能损害:"}, {"probability": {"variance": 0.003277, "average": 0.977961, "min": 0.697416}, "location": {"width": 771, "top": 841, "height": 28, "left": 236}, "words": "卡培他滨应用于肾功能损害患者时须谨慎同5氟尿嘧啶一样,中度賢功能损害患者(肌"}, {"probability": {"variance": 0.001948, "average": 0.981825, "min": 0.774132}, "location": {"width": 795, "top": 880, "height": 29, "left": 195}, "words": "酐清除率为30-50mL/min[ Cockroft和 Gault))治疗相关3或4级不良反应事件的发生率较高"}, {"probability": {"variance": 0.00982, "average": 0.953233, "min": 0.517389}, "location": {"width": 813, "top": 921, "height": 27, "left": 195}, "words": "对中度肾功能损害患者(肌酐清除率为30-50mL/min[ Cockroft和 Gault),建议卡培他滨的起"}, {"probability": {"variance": 0.002804, "average": 0.983867, "min": 0.691999}, "location": {"width": 817, "top": 960, "height": 27, "left": 194}, "words": "始给药剂量减为标准剂量的75%。这一剂量调整建议既适用于卡培他滨单药治疗、也适用"}, {"probability": {"variance": 0.003659, "average": 0.982777, "min": 0.685528}, "location": {"width": 813, "top": 998, "height": 28, "left": 199}, "words": "于卡培他滨联合治疗,如患者出现2-4级不良事件,应严密监测并立即暂停给药,随后的剂"}, {"probability": {"variance": 8.8e-05, "average": 0.994821, "min": 0.961494}, "location": {"width": 313, "top": 1039, "height": 25, "left": 195}, "words": "量调整可参考相应的剂量调整表格"}, {"probability": {"variance": 1e-06, "average": 0.999011, "min": 0.996412}, "location": {"width": 112, "top": 1079, "height": 24, "left": 198}, "words": "肝功能损害:"}, {"probability": {"variance": 0.005268, "average": 0.979321, "min": 0.575122}, "location": {"width": 775, "top": 1114, "height": 27, "left": 236}, "words": "卡培他滨用于肝功能损害患者时应密切监测。非胖转移引起的肝损伤或严重肝损伤对卡"}, {"probability": {"variance": 8.9e-05, "average": 0.994456, "min": 0.953493}, "location": {"width": 668, "top": 1153, "height": 30, "left": 199}, "words": "培他滨体内分布的影响尚不明确(见特殊人群的药代动力学和特殊用药指南"}, {"probability": {"variance": 2.1e-05, "average": 0.997835, "min": 0.983042}, "location": {"width": 240, "top": 1234, "height": 26, "left": 202}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.05132, "average": 0.592459, "min": 0.414245}, "location": {"width": 101, "top": 1208, "height": 71, "left": 914}, "words": "产卫"}, {"probability": {"variance": 0.00069, "average": 0.973483, "min": 0.947221}, "location": {"width": 44, "top": 1276, "height": 24, "left": 200}, "words": "妊娠"}, {"probability": {"variance": 0.000201, "average": 0.994521, "min": 0.915897}, "location": {"width": 774, "top": 1312, "height": 28, "left": 239}, "words": "未进行卡培他滨用于妊娠妇女的研究。基于卡培他滨的药理毒理性质,可推断出卡培他"}, {"probability": {"variance": 0.000126, "average": 0.995868, "min": 0.934231}, "location": {"width": 807, "top": 1353, "height": 26, "left": 197}, "words": "滨用于妊娠妇女可能引起胎儿损伤。在动物生殖毒性研究中,卡培他滨引起胚胎死亡和畸形"}, {"probability": {"variance": 5.2e-05, "average": 0.996863, "min": 0.964454}, "location": {"width": 815, "top": 1391, "height": 28, "left": 198}, "words": "这些发现均在氟嘧啶衍生物的预期效应范围内。卡培他滨可能是一种人类致畸剂。妊娠期间"}, {"probability": {"variance": 0.000104, "average": 0.994045, "min": 0.95381}, "location": {"width": 817, "top": 1431, "height": 26, "left": 197}, "words": "禁止使用卡培他滨。如果妊娠期间使用卡培他滨,或患者在用药期间怀孕,应告知患者该药"}, {"probability": {"variance": 0.000128, "average": 0.996254, "min": 0.935517}, "location": {"width": 641, "top": 1469, "height": 28, "left": 198}, "words": "对胎儿的潜在风险。应劝告育龄妇女在接受卡培他滨治疗期间避免怀孕"}, {"probability": {"variance": 0.000226, "average": 0.980372, "min": 0.95736}, "location": {"width": 106, "top": 1510, "height": 26, "left": 200}, "words": "哺乳期妇女"}], "language": 3}